semaglutide and ckd Kidney Survival Benefits of in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses FLOWing with the SemagluTIDE —

Clinical trials published in 2025 established this combination as producing the highest weight loss observed with pharmaceutical interventions to date, with 60% of participants achieving at least 20% body weight reduction over 68 weeks

Additionally, future research should explore whether adjunctive therapies, such as resistance training or bone-specific pharmacologic interventions, could counteract potential bone resorption associated with weight loss or be superior to GLP-1s

Its best to avoid alcohol when using GLP-1 receptor agonists like Wegovy and Ozempic

Pharmacopeia and CDC recommend discarding any opened BAC water after 28 days

Of these live births, 2 babies (1.8% of total) had congenital anomalies while 51 babies were born without reported birth defects